Expanded Sublative Indication to be Unveiled at AMWC in Monaco
LONDON, April 3, 2014 /CNW/ - Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today that its proprietary Sublative™ technology has received CE Mark indication for the effective treatment of striae (stretch marks) and acne scars. The new treatment protocols are now available on all of the Syneron Sublative compatible systems, which include elōs Plus™, eTwo™ and eMatrix™.
Stretch marks are one of the most common skin disorders, impacting 95% of women during puberty or pregnancy, and can also occur in men and children. Historically difficult to treat, striae occur when the skin is stretched from rapid growth or weight gain, and causes damage to the connective tissue in the dermis.
Acne is a common condition experienced by up to 85% of adolescents and young adults and 5% of older adults. In some patients, the healing process results in permanent, disfiguring scars. Treatments ranged from chemical peels to ablative procedures with long recovery times and risky side effects.
With its new CE Mark clearance, Sublative has been shown to be an effective and safe way to reduce the appearance of stretch marks, acne scars and other skin irregularities in all skin types with minimal side effects, discomfort or downtime. The unique patented technology uses fractionated bi-polar radiofrequency directed to the skin in the form of a matrix. Due to its unique design, energy is deposited in the skin to initiate a healing response with minimal epidermal disruption. Patients benefit from a comfortable treatment with significant outcomes avoiding the potential complications of more aggressive treatments. After treatment with Sublative, the appearance of stretch marks and acne scars are greatly reduced.
"We have extensively studied the Sublative approach in the treatment of striae and found a noticeable and measurable improvement in the depth, width and color of striae after very few treatments," states Maurice Adatto, M.D., Dermatologic Surgeon, Geneva, Switzerland, founder & Medical Director of SKINPULSE Derm & Laser Centres, Lecturer at Bern University Hospital.
The typical Sublative protocol consists of three to five treatments, spaced four to six weeks apart. Post treatment, patients can expect tone and texture improvements as a result of increased levels of collagen and elastin and new healthy skin cells, which are produced.
"Sublative resurfacing is my first line therapy for acne scarring, particularly for skin types IV - VI." said Amy Taub, MD from Chicago, Illinois, founder and Medical Director of Advanced Dermatology and skinfo, Clinical Assistant Professor at Northwestern University, Feinberg School of Medicine, and added: "I find it to be superior to non-ablative laser resurfacing with respect to downtime, discomfort and degree of complications such as acne and post inflammatory hyperpigmentation."
The addition of stretch mark treatment further expands Syneron's clinical utility and will allow physician customers to address a large segment of the aesthetic market. "We have received very positive physician and patient feedback on the Sublative technology since its introduction in 2009," states Amit Meridor, Syneron's CEO. "This patented fractional bi-polar radio frequency technology delivers excellent outcomes with little-to-no downtime and is a safe and more effective treatment alternative for all skin tones. We continue to create innovation solutions that further drive the aesthetic industry forward."
Syneron will unveil the Striae and acne scars treatment protocols for its Sublative compatible platforms at the 12th Annual Anti-Aging Medicine World Congress in Monte Carlo, Monaco from April 3-5, 2014.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE: Syneron Medical Ltd.
For further information: Zack Kubow, The Ruth Group? +1-646-536-7020? firstname.lastname@example.org; Hugo Goldman, Chief Financial Officer Hugo.Goldman@syneron.com; Syneron Medical - Public Relations - email@example.com